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The new Italian cytological classification (2014) of thyroid nodules replaced the TIR3 category of the old classification (2007) with
two subclasses, TIR3A and TIR3B, with the aim of reducing the rate of surgery for benign diseases. Moreover, thyroid imaging
reporting and data system (TI-RADS) score appears to ameliorate the stratification of the malignancy risk. We evaluated
whether the new Italian classification has improved diagnostic accuracy and whether its association with TI-RADS score could
improve malignancy prediction. We retrospectively analyzed 70 nodules from 70 patients classified as TIR3 according to the old
Italian classification who underwent surgery for histological diagnosis. Of these, 51 were available for cytological revision
according to the new Italian cytological classification. Risk of malignancy was determined for TIR3A and TIR3B, TI-RADS
score, and their combination. A different rate of malignancy (p = 0 0286) between TIR3A (13.04%) and TIR3B (44.44%) was
observed. Also TI-RADS score is significantly (p = 0 003) associated with malignancy. By combining cytology and TI-RADS
score, patients could be divided into three groups with low (8.3%), intermediate (21.4%), and high (80%) risk of malignancy. In
conclusion, the new Italian cytological classification has an improved diagnostic accuracy. Interestingly, the combination of
cytology and TI-RADS score offers a better stratification of the malignancy risk.
1. Introduction
Palpable thyroid nodules are present in about 4–7% of the
adult population in countries with adequate iodine intake
and up to 20% in iodine insufficient areas [1, 2]. High-
resolution ultrasound can detect thyroid nodules in 19–68%
of randomly selected individuals with higher frequencies in
women and elderly [2, 3]. Since about 5% of patients
affected by thyroid nodules harbour a malignant lesion, the
first aim in their evaluation is to exclude malignancy [4].
To this end, fine-needle aspiration cytology (FNAC) repre-
sents the diagnostic cornerstone because of its diagnostic
accuracy, reproducibility, and cost-effectiveness [5–8]. How-
ever, FNAC is characterized by a grey diagnostic area in
which the indeterminate cytology precludes a distinction
between benign and malignant lesions [9]. Surgical excision,
frequently necessary to obtain a definitive diagnosis, shows
that about 80% of these patients harbour a benign lesion [9].
In order to reduce unnecessary thyroidectomy, a number
of instrumental and molecular diagnostic approaches
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have been proposed [10–27]. In addition, new classifica-
tion systems for thyroid cytology have been designed. In
particular, in the Bethesda System for Reporting Thyroid
Cytopathology (BSRTC), indeterminate nodules have
been subcategorized in atypia or follicular lesions of
undetermined significance (AUS/FLUS) and in follicular
neoplasms or suspicious for follicular neoplasms (FN/
SFN) which are expected to correspond to different rate of
malignancy with different clinical action required [23]. In
2009, the British Thyroid Association-Royal College of
Pathologists (BTA-RCPath) revised the previous British
reporting system already in use in UK since 2007 along
the lines of the BSRTC and split the Thy 3 category in Thy
3a and Thy 3f [28]. In 2014, the Italian Society for Anatomic
Pathology and Cytology (SIAPEC) together with the Italian
Thyroid Association (AIT) modified the previous thyroid
cytology classification of 2007, by replacing the TIR3 class
with two new subclasses, TIR3A and TIR3B [24–26]. The
latter are comparable both to the BSRTC AUS/FLUS and
FN/SFN classes and to the BTA-RCPath classes Thy 3a and
Thy 3f [26]. However, unlike the BSRTC and BTA-RCPath,
the SIAPEC extends TIR3B to include those cases with
“mild/focal nuclear atypia” suggestive of papillary carcinoma
that are expected to be at higher risk of malignancy [24].
The present study was conducted with the aim of
evaluating whether the malignancy rate of TIR3A and
TIR3B differs, thus improving the clinical management of
patients with lesions classified in the TIR3 category in
the previous classification. To this end, cytological smears
of 51 nodules from patients thyroidectomized following
TIR3 diagnosis were independently reevaluated by the same
three cytopathologists, who made the initial TIR3 cytological
diagnosis, according to the new SIAPEC 2014 classification.
In addition, we evaluated whether the thyroid imaging repor-
ting and data system (TI-RADS) score, either alone or in
combination with the SIAPEC 2014 cytological diagnosis,
could be of any value in predicting malignancy.
2. Materials and Methods
2.1. Patients. The series comprises 70 patients (52 females
and 18males, median age 58, range 13–77 yr) who underwent
fine-needle aspiration cytology (FNAC) in the period between
January 2005 and December 2013. Patients provided their
written informed consent. All of them had a TIR3 diagnosis
based on the old Italian cytological classification (SIAPEC
2007) and were submitted to surgical excision for histological
diagnosis, as shown in Table 1. Of the 70 cases, cytological
smears were available for 51 patients. Of the latter, one patient
with histological diagnosis of uncertain malignant poten-
tial was excluded from the analysis. All smears were inde-
pendently reevaluated by the same three cytopathologists
(FN, VA, and DB), who made the initial TIR3 cytological
diagnosis, according to the new SIAPEC 2014 classification,
blinded for histology.
2.2. Ultrasound and Color-Flow Doppler. Thyroid ultraso-
nography (US) was performed in 69 patients using a Toshiba
Aplio XV system equipped with a linear transducer (PLT-
805AT). The nodule classification was based on echogenicity
and echostructure: solid hypoechoic, solid isoechoic, solid
hyperechoic, mixed, or anechoic. Anteroposterior (APD),
transverse (TD), and longitudinal (LD) diameters of the nod-
ules were used to obtain the volume of the nodules, based on
the formula of ellipsoid: Volume = APD × TD × LD × π/6.
Nodule margin was defined regular or irregular. Micro-
calcifications, defined as hyperechoic spots < 22mm, were
recorded. The pattern of nodular vascular signal was evaluated
by color-flow Doppler (CFD) and defined as CFD 1, as an
absent signal; CFD 2, as a perinodular spot signal; and CFD
3, as a perinodular and/or intranodular signal. Ultrasound
examinations were performed by two observers (AN, EDA)
with an agreement on the US and CFD characteristics
greater than 95%. US features, such as hypoechogenicity,
irregular margins, microcalcifications, and taller-than-wide
shape, were used to calculate the TI-RADS score as described
by Kwak et al. [16].
2.3. Fine-Needle Aspiration Cytology. All patients were
instructed not to take aspirin or any other anticoagulants 5
days prior to thyroid nodule aspiration. A 23–27 gauge
needle, attached to 20ml plastic syringes, was used to aspirate
nodules. All aspirates were smeared directly on 4–6 glass slides
and stained by May-Grunwald-Giemsa and Papanicolaou.
Cytological specimens of the 70 patients had been evaluated
by three cytopathologists (FN, VA, and DB) from the same
institution. All 70 nodules had a TIR3 cytological diagnosis,
based on the SIAPEC 2007 classification: TIR1, nondiagnostic;
TIR2, negative for malignant cells; TIR3, indeterminate
(follicular lesion); TIR4, suspicious for malignancy; and
TIR5, diagnostic of malignancy [24]. Of these 70 cases, cyto-
logical smears were available for 51 nodules, which were
reevaluated collegially by the same three cytopathologists
according to the new SIAPEC 2014 classification [24]. In
particular, these cases were reevaluated and classified either
as TIR3A (low-risk indeterminate lesion) or as TIR3B (high-
risk indeterminate lesion). Discordant diagnosis was resolved
by a consensus review.
2.4. Histological Outcome. Histological diagnoses of patients
who had undergone surgery were used as gold standard for
correlation with the cytological interpretations according to
the WHO classification currently in use (Table 1) [29].
2.5. Statistical Analysis. Patients’ age and mean nodular
volume in benign versus malignant thyroid nodules were
compared by the nonparametric Mann–Whitney U test, while
clinical, US, and CFD characteristics were compared by the
χ2 test or the Fisher exact test. The statistical significance
was set at p < 0 05.
3. Results
Following total thyroidectomy, histological diagnosis showed
that, of the 70 patients with indeterminate lesions, 17 (24.3%,
13 females and 4 males) had a malignant lesion. Of these,
2 had follicular thyroid carcinoma (FTC) and 15 papillary
thyroid carcinoma (PTC), ofwhich 12 classical and 3 follicular
variants, and 1 had a well-differentiated tumor of uncertain
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Table 1: Demographic, ultrasonographic, cytological, and histological parameters of 70 patients affected by indeterminate thyroid
lesions. TI-RADS, thyroid imaging reporting and data system; FTC, follicular thyroid cancer; FA, follicular adenoma; CV-PTC,
classical variant of papillary thyroid carcinoma; FV-PTC, follicular variant of papillary thyroid carcinoma; NH, nodular hyperplasia;
CLT, chronic lymphocytic thyroiditis; WDT-UMP, well-differentiated tumor-uncertain malignant potential; HA, Hürthle adenoma.
Nodule volume is expressed in milliliters.
Number Sex Age Nodule volume SIAPEC 2007 SIAPEC 2014 Nodule histological diagnosis TI-RADS score
1 M 20 2.268 TIR3 TIR3B FTC 4c
2 F 24 0.252 TIR3 TIR3A FA 4c
3 F 28 4.18 TIR3 TIR3A CV-PTC 4c
4 F 35 0.432 TIR3 TIR3A FV-PTC 4c
5 M 36 0.99 TIR3 TIR3A NH 4c
6 F 41 0.495 TIR3 TIR3B CV-PTC 5
7 F 42 1.607 TIR3 TIR3B NH 4b
8 F 43 0.45 TIR3 TIR3B CV-PTC 4c
9 F 50 0.243 TIR3 TIR3B CV-PTC 4c
10 M 52 2.2 TIR3 TIR3A NH 4b
11 M 54 1.296 TIR3 TIR3A NH 4b
12 F 55 2.66 TIR3 TIR3B NH 4b
13 F 55 4.9 TIR3 TIR3A NH 4a
14 F 58 1.26 TIR3 TIR3A FA 4c
15 M 58 4.568 TIR3 TIR3A NH 3
16 F 61 0.18 TIR3 TIR3B NH 4c
17 F 62 3.658 TIR3 TIR3A NH 4c
18 F 64 0.99 TIR3 TIR3A CLT 3
19 F 66 1.08 TIR3 TIR3A NH 4c
20 F 68 0.096 TIR3 TIR3B CV-PTC 4c
21 F 69 0.2 TIR3 TIR3B NH 4b
22 F 69 0.792 TIR3 TIR3A WDT-UMP 4c
23 F 72 1.08 TIR3 TIR3A FA 4b
24 F 75 3.12 TIR3 TIR3B CV-PTC 4b
25 F 52 0.123 TIR3 TIR3B NH 4c
26 F 63 2.025 TIR3 TIR3B NH 4a
27 F 64 0.264 TIR3 TIR3B CV-PTC 4b
28 F 73 0.49 TIR3 TIR3A NH 4c
29 M 57 0.756 TIR3 TIR3B CV-PTC 4b
30 F 60 0.484 TIR3 TIR3B NH 4b
31 M 40 1.344 TIR3 TIR3B NH 4a
32 F 57 0.24 TIR3 TIR3A NH 4b
33 M 32 1.08 TIR3 TIR3B NH 4a
34 F 45 0.196 TIR3 TIR3B FV-PTC 4c
35 F 13 0.576 TIR3 TIR3A NH 4c
36 F 27 8.58 TIR3 TIR3A NH 4a
37 F 46 0.168 TIR3 TIR3B CV-PTC 4c
38 F 58 2.04 TIR3 TIR3B FA 4b
39 M 56 3.105 TIR3 TIR3B NH 4a
40 F 63 0.75 TIR3 TIR3A NH 4a
41 F 67 4.774 TIR3 TIR3B FA 4b
42 M 49 0.364 TIR3 TIR3B FV-PTC 4b
43 F 56 0.216 TIR3 TIR3B CV-PTC 4c
44 F 64 0.96 TIR3 TIR3A NH 4a
45 M 64 1.53 TIR3 TIR3B NH 4b
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malignant potential. The remaining 52 patients (74.3%, 38
females and 14 males) were affected by benign lesions, inclu-
ding 10 follicular adenoma, 40 nodular hyperplasia, 1 Hürthle
adenoma, and 1 chronic lymphocytic thyroiditis.
We initially evaluated the role of gender, patient’s age at
diagnosis, size of the lesion, ultrasound, and color-flow
Doppler features in predicting malignancy. No significant
association was observed for gender, median age at diagnosis,
echostructure, nodularity, and color-flow Doppler between
benign and malignant lesions (Table 2). On the other hand,
lower median nodule’s volume (p = 0 016), taller-than-wide
nodule’s shape (p = 0 046), irregularmargin (p = 0 008),micro-
calcifications (p = 0 043), and hypoechogenicity (p = 0 021) are
associated with nodule malignancy (Table 2).
We next evaluated whether the TI-RADS score is associ-
ated with lesion’smalignancy and found a positive correlation
between TI-RADS score and risk of malignancy (p = 0 003)
(Table 3).
Since cytological smears were available for 51 of the 70
patients, they were independently reevaluated by the same
three cytopathologists who provided the initial diagnosis
according to the new SIAPEC 2014 classification, in which
the TIR3 category was replaced by two subclasses, TIR3A
and TIR3B. A concordant diagnosis was reached in 32 cases.
The 19 (37.2%) cases with discordant diagnosis were resolved
by a consensus review. From the 51 cases, however, the single
patient with histological diagnosis of uncertain malignant
potential was excluded from the analysis. The results showed
a difference in the rate of malignancy (p = 0 0286) between
the TIR3A and TIR3B lesions (Table 4).
In the attempt to stratify indeterminate lesions according
to the risk of malignancy, we combined cytology and TI-
RADS score. In particular, the TIR3A and TIR3B categories
were dichotomized based on TI-RADS score, as reported in
Table 5. As it may be noticed, the TIR3A combined with
the TI-RADS scores 3, 4a, and 4b showed a low malignancy
rate (8.3%). On the other hand, the TIR3A combined with
the TI-RADS scores 4c and 5, as well as the TIR3B combined
with the TI-RADS scores 3, 4a, and 4b, showed an intermedi-
ate risk of malignancy (20.9%). Lastly, the TIR3B combined
with the TI-RADS scores 4c and 5 showed a high risk of
malignancy (80%). These results lead us to propose a new
stratification of the risk of malignancy for indeterminate
lesions in low, intermediate, and high as reported in Table 6.
4. Discussion
Over the last years, major efforts have been made to generate
new classification systems for thyroid cytology in order to
ameliorate the diagnostic stratification of nodules with inde-
terminate cytology, a grey area of fine-needle aspiration
cytology [23–28]. In particular, all the new systems have
Table 1: Continued.
Number Sex Age Nodule volume SIAPEC 2007 SIAPEC 2014 Nodule histological diagnosis TI-RADS score
46 F 73 1.755 TIR3 TIR3B NH 4a
47 F 42 1.19 TIR3 TIR3A NH 4c
48 F 77 2.7 TIR3 TIR3B NH 4b
49 F 68 7.038 TIR3 TIR3A FTC 4a
50 M 65 1.615 TIR3 TIR3A FA 4c
51 F 70 0.88 TIR3 TIR3A HA 4b
52 M 40 10.93 TIR3 — NH 4b
53 F 63 1.02 TIR3 — NH 4a
54 F 31 12.18 TIR3 — NH 3
55 F 50 1.836 TIR3 — NH 3
56 F 63 2.432 TIR3 — NH 4a
57 F 66 1.224 TIR3 — NH 4c
58 M 16 0.32 TIR3 — FA 4a
59 M 24 1.368 TIR3 — FA 4c
60 M 69 0.825 TIR3 — NH 4b
61 F 43 0.336 TIR3 — NH 4b
62 F 71 0.833 TIR3 — NH 4b
63 F 40 2.835 TIR3 — NH 4a
64 M 59 0.216 TIR3 — CV-PTC 4c
65 F 70 0.41 TIR3 — NH 4b
66 M 65 0.462 TIR3 — FA 4c
67 F 36 0.16 TIR3 — NH 3
68 F 39 0.484 TIR3 — NH 4a
69 F 56 0.672 TIR3 — CV-PTC 4c
70 F 67 4.641 TIR3 — FA 3
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subcategorized the indeterminate lesions into two subclasses
which are expected to correspond to different rate of malig-
nancy. In particular, in the AUS/FLUS category of the
BSRTC, in the Thy 3a category of the BTA-RCPath, and
in the category TIR3A of the SIAPEC 2014, a low rate of
malignancy (5–15%) is expected, while a significantly higher
rate, comprised between 15% and 30%, is expected in the
FN/SFN category of the BSRTC, in the Thy 3f category of
the BTA-RCPath, and in the TIR3B category of the SIAPEC
2014. Importantly, these new diagnostic classifications are
expected to drive the clinical management of patients. In
fact, in view of the relative low rate of malignancy of the
AUS/FLUS, Thy 3a and TIR3A categories, follow-up of the
patients and FNAC repetition is suggested. On the other
hand, the relative high rate of malignancy observed in the
FN/SFN, Thy 3f, and TIR3B recommends surgery as the
preferential option [23–28]. However, a study from Brophy
and colleagues, using the BTA-RCPath classification system
on 151 Thy 3 nodules with histological diagnosis, found no
difference in the malignancy rate of lesions classified as
Thy 3a and Thy 3f [30]. In particular, although the authors
observed a slightly higher malignancy rate in Thy 3f cases
(17.9%) than in Thy 3a cases (13.4%), this difference was
not significant. In addition, similar findings emerged from a
recent meta-analysis of 51 studies, using the BSRTC classifi-
cation system on a total of 4475 AUS/FLUS and 3202 FN/
SFN nodules, showing a 27% rate of malignancy for the
AUF/FLUS FNAC and 31% for the FN/SFN FNACs [31].
In the latter of relevance is the high rate of malignancy
observed in the AUS/FLUS categories, with respect to the
expectations of BSRTC. In this context, studies attempting
to perform a 2-tier subclassification of the AUS/FLUS
categories in order to achieve a more accurate estimate of
the risk of malignancy have been reported [32, 33].
The data reported here are not in agreement with the
above studies because in our series, a significant difference
could be observed between the rates of malignancies of
TIR3A and TIR3B cases. In fact, in TIR3A category, we
found a slight higher rate of malignancy (13%), with respect
to the expected one (<10%), while TIR3B category had a
higher malignant rate (44%), with respect to the expected
one (20%) [26]. These data demonstrated that the new SIA-
PEC 2014 provides a better stratification of the malignancy
risk for indeterminate lesions, with respect to previous SIA-
PEC 2007 classification [26]. With respect to the BSRTC
and BTA-RCPath, it must be emphasized that, in the SIAPEC
2014 Italian classification, the TIR3B subcategory includes
samples characterized by nuclear alterations suggestive of
papillary carcinoma that are too mild or focal to be included
in the TIR4 category. Even if our data derive from a relatively
small series of cases, they are in line with the referred increas-
ing evidence that the AUS/FLUS with cytological atypia is the
AUS/FLUS subcategory most frequently associated with
malignancy [34]. It has to be said, however, that the consensus
review of the cytological smears by three different cytopathol-
ogists (also suggested by the BSRTC in challenging cases)
could have affected the outcome of TIR3 subclassification
in TIR3A and TIR3B, representing a possible confounding
Table 3: Malignancy rate according to TI-RADS score in 69
indeterminate lesions.
TI-RADS
score
Number of cases
Benign
(n, %)
Malignant
(n, %)
p
3 3 3 (100%) 0 (0%)
0.003
4a 16 16 (100%) 0 (0%)
4b 24 19 (79.2%) 5 (20.8%)
4c 25 14 (56%) 11 (44%)
5 1 0 1 (100%)
Table 4: Malignancy rate of the SIAPEC 2014 classification of 50
indeterminate lesions with indeterminate cytological diagnosis.
Benign (n = 35) Malignant (n = 15) p
TIR3A (n = 23) 20 (86.96%) 3 (13.04%)
TIR3B (n = 27) 15 (55.56%) 12 (44.44%) 0.0286
Table 2: Association of clinical and ultrasonographic (US) features
with histology of 69 nodules with indeterminate cytological diagnosis.
CFD, color-flow Doppler.
Clinical and US features
Benign
(n = 52)
Malignant
(n = 17) p
Gender
Male 14 (26.29%) 4 (23.52%)
0.527
Female 38 (73.1%) 13 (76.47%)
Age (yr)
Median age 58 (13–77) 50 (20–75) 0.347
Morphology
Taller than wide 7 (13.46%) 6 (35.3%)
0.046
Round/oval shape 45 (86.53%) 11 (64.70%)
Median nodule
volume (ml)
1.2 (0.12–12) 0.44 (0.1–8.6) 0.016
Margin
Irregular 15 (28.8%) 11 (64.70%)
0.008
Regular 37 (71.1%) 6 (35.3%)
Microcalcification
Yes 9 (17.30%) 7 (41.2%)
0.043
No 43 (82.7%) 10 (58.9%)
Echogenicity
Hypoechogen 25 (48.1%) 13 (76.47%)
0.021
Isoechogen 19 (36.5%) 1 (5.88%)
Echostructure
Mixed 8 (15.4%) 3 (17.64%)
0.545
Solid 44 (84.6%) 14 (82.35%)
Color-flow Doppler
CFD 1 11 (21.15%) 5 (29.41%)
0.755CFD 2 6 (11.5%) 1 (5.88%)
CFD 3 35 (67.30%) 11 (64.70%)
Nodularity
Uninodular 20 (38.5%) 5 (29.41%)
0.356
Multinodular 32 (61.53%) 12 (70.6%)
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factor with respect to one observer performance [35, 36]. In
this context, it is also worth mentioning that, in 37.2% (in 19
out of 51) of cases, a discordant diagnosis was made by the
three different cytopathologists, which was then resolved
by a consensus review of the cytological smears. This is not
surprising since it is well known in the literature that the
major interobserver discordance is observed in the indeter-
minate lesions [37].
However, also with this classification, more than half of
TIR3B patients undergo unnecessary surgery. The ability of
TI-RADS score in predicting thyroid nodule malignancy
has been demonstrated [17]. This was confirmed in the
present study also for indeterminate lesions, in which a sig-
nificant association between high-risk TI-RADS score and
malignancy is observed. For this reason, we attempted to
ameliorate the accuracy of the SIAPEC 2014 thyroid cyto-
logical classification by combining it with the TI-RADS
score. In particular, dichotomizing the TIR3A and TIR3B
categories based on low-risk TI-RADS score (3, 4a, and
4b) and high-risk TI-RADS score (4c and 5), the risk of
malignancy for indeterminate lesions could be stratified in
three classes: low (below 10%), intermediate (about 20%),
and high (about 80%). Similar results were recently reported
by Maia and colleagues using the Bethesda system and by
Chng and colleagues using the BTA-RCPath system [38, 39].
5. Conclusions
Compared to the old SIAPEC 2007, the new SIAPEC 2014
thyroid cytological classification has improved diagnostic
accuracy, reducing the numbers of patients with indetermi-
nate lesions requiring surgery. The combination of SIAPEC
2014 thyroid cytological classification and TI-RADS score
could offer a better stratification of the malignancy risk
suggesting a conservative approach for low-risk class and
a surgical approach for high-risk class. For patients with
intermediate risk, a careful evaluation of risk factors for
thyroid malignancy and a close follow-up is recommended.
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